Objective: The present study aims at systematically reviewing research conducted on factors promoting breast, cervical and colorectal cancer screenings participation.
Methods: A literature search in MEDLINE/PubMed and PsycInfo from January 2017 to October 2021 was performed. Data extraction, researchers' full agreement and the inclusion criteria produced 102 eligible studies. Data were narratively synthesized and critically interpreted.
Results: Multiple factors favoring or hindering breast, cervical and colorectal cancer screenings were identified and summarized as factors operating at the individual level (background information, individual characteristics, emotions related to screening procedure and to cancer, knowledge and awareness), at the relational level (relationships with healthcare staff, significant others, community members), and at the healthcare system level (systems barriers/policy, lack of staff). A critical appraisal of studies revealed a fragmentation in the literature, with a compartmentalization of studies by type of cancer screening, country and specific populations of destination.
Conclusions: Overall findings indicated that greater integration of research results obtained independently for each cancer diagnosis and within the different countries/populations could foster a more comprehensive understanding of factors potentially enhancing the participation in breast, cervical and colorectal cancer screenings worldwide. This review, which is grounded in the current context of globalization and superdiversification in population, can help to enhance a better integration between research and practices, by supporting the development of more effective and inclusive evidence-based interventions and health-promotion campaigns worldwide. Research and practical implications are highlighted and discussed.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541457 | PMC |
http://dx.doi.org/10.1002/pon.5997 | DOI Listing |
BMJ Oncol
August 2024
Medical Oncology, Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India.
Objective: Older patients with cancer have traditionally been under-represented in global clinical trials. There are no data from India regarding this issue.
Methods And Analysis: This was a retrospective analysis done at our institute on interventional studies conducted between 2003 and 2023 in adult patients with malignancies.
AJPM Focus
February 2025
Department of Population and Public Health Sciences, Keck School of Medicine, University of Southern California, Los Angeles, California.
Introduction: The authors determined whether certain subgroups of patients with cancer on Ohio Medicaid benefited from the program's expansion to a greater/lesser extent. Study outcomes included stage at diagnosis for screening-amenable cancers (breast [=1,707 and 2,976], cervical [=309 and 655], and colorectal [=927 and 2,009] cancer, before and after expansion, respectively) and time to treatment initiation.
Methods: Using linked data from the 2011-2017 Ohio cancer registry and Medicaid, the authors conducted a robust Poisson regression analysis for stage at diagnosis and Cox regression analysis for time to treatment initiation to obtain the adjusted risk for earlier stage at diagnosis before to after expansion or hazard of shorter time to treatment initiation for each demographic or clinical subgroup after compared with before pre-Medicaid expansion.
Phys Imaging Radiat Oncol
January 2025
Department of Radiation Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
The McNamara (MCN) and Wedenberg (WED) RBE weighted dose (D), dose and dose-weighted average LET (LET) were calculated in twenty brain cancer patients. A linear approximation was made for each RBE model to give best agreement to clinically relevant dosimetric parameters. Additional evaluations were done on twenty head and neck and twenty breast cancer patients.
View Article and Find Full Text PDFBMC Public Health
January 2025
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Background: Disparities in lung cancer outcomes persist among Black Americans, necessitating targeted interventions to address screening inequities. This paper reports the development and refinement of Witness Project Lung, a community-based initiative tailored to the specific needs of the Black community, aiming to improve awareness and engagement with lung cancer screening.
Methods: Utilizing a user-centered design and guided by the original Witness Project framework - an evidence-based lay health advisor intervention program originally developed to increase knowledge and awareness about breast cancer risk and screening in the Black community and later trans-created to the cervical and colorectal cancer screening contexts - Witness Project Lung was developed and refined through qualitative input from key stakeholders in the Black faith community.
Int J Biol Macromol
January 2025
Precision Medicine Center, Scientific Research Center, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China. Electronic address:
The use of natural products for cancer treatment has a lengthy history. The safety and multifunctionality of naturally occurring substances have rendered them appropriate for cancer treatment. Curcumin influences multiple molecular pathways and is advantageous for treating both hematological and solid tumors.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!